Summary

Gastric Motility Disorder Drugs Market – Scope of Report
TMR’s report on the global gastric motility disorder drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global gastric motility disorder drugs market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global gastric motility disorder drugs market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the gastric motility disorder drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global gastric motility disorder drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global gastric motility disorder drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global gastric motility disorder drugs market.

The report delves into the competitive landscape of the global gastric motility disorder drugs market. Key players operating in the global gastric motility disorder drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global gastric motility disorder drugs market profiled in this report.

Key Questions Answered in Global gastric motility disorder drugs Market Report
• What is the sales/revenue generated by gastric motility disorder drugs across all regions during the forecast period?
• What are the opportunities in the global gastric motility disorder drugs market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Gastric Motility Disorder Drugs Market – Research Objectives and Research Approach
The comprehensive report on the global gastric motility disorder drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global gastric motility disorder drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global gastric motility disorder drugs market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Gastric Motility Disorder Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Gastric Motility Disorder Drugs Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Gastric Motility Disorder Drugs Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2020-2034
6.3.1. Antacids
6.3.2. Antidiarrheals
6.3.3. Calcium-channel Blockers
6.3.4. H2 Blockers
6.3.5. Others (Proton Pump Inhibitors, etc.)
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Gastric Motility Disorder Drugs Market Analysis and Forecast, by Disorder Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Disorder Type, 2020-2034
7.3.1. Upper Digestive Tract
7.3.1.1. Achalasia
7.3.1.2. Gastroesophageal Reflux Disease (GERD)
7.3.1.3. Gastroparesis
7.3.1.4. Dumping Syndrome
7.3.2. Lower Digestive Tract
7.3.2.1. Intestinal Pseudo-obstruction
7.3.2.2. Small Intestinal bacterial Overgrowth (SIBO)
7.3.2.3. Pelvic Dyssynergia
7.3.2.4. Hirschsprung’s Disease
7.4. Market Attractiveness Analysis, by Disorder Type
8. Global Gastric Motility Disorder Drugs Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2020-2034
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Gastric Motility Disorder Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Gastric Motility Disorder Drugs Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Class, 2020-2034
10.3.1. Antacids
10.3.2. Antidiarrheals
10.3.3. Calcium-channel Blockers
10.3.4. H2 Blockers
10.3.5. Others (Proton Pump Inhibitors, etc.)
10.4. Market Value Forecast, by Disorder Type, 2020-2034
10.4.1. Upper Digestive Tract
10.4.1.1. Achalasia
10.4.1.2. Gastroesophageal Reflux Disease (GERD)
10.4.1.3. Gastroparesis
10.4.1.4. Dumping Syndrome
10.4.2. Lower Digestive Tract
10.4.2.1. Intestinal Pseudo-obstruction
10.4.2.2. Small Intestinal bacterial Overgrowth (SIBO)
10.4.2.3. Pelvic Dyssynergia
10.4.2.4. Hirschsprung’s Disease
10.5. Market Value Forecast, by Distribution Channel, 2020-2034
10.5.1. Hospital Pharmacies
10.5.2. Retail Pharmacies
10.5.3. Online Pharmacies
10.6. Market Value Forecast, by Country, 2020-2034
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Drug Class
10.7.2. By Disorder Type
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Gastric Motility Disorder Drugs Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Class, 2020-2034
11.3.1. Antacids
11.3.2. Antidiarrheals
11.3.3. Calcium-channel Blockers
11.3.4. H2 Blockers
11.3.5. Others (Proton Pump Inhibitors, etc.)
11.4. Market Value Forecast, by Disorder Type, 2020-2034
11.4.1. Upper Digestive Tract
11.4.1.1. Achalasia
11.4.1.2. Gastroesophageal Reflux Disease (GERD)
11.4.1.3. Gastroparesis
11.4.1.4. Dumping Syndrome
11.4.2. Lower Digestive Tract
11.4.2.1. Intestinal Pseudo-obstruction
11.4.2.2. Small Intestinal bacterial Overgrowth (SIBO)
11.4.2.3. Pelvic Dyssynergia
11.4.2.4. Hirschsprung’s Disease
11.5. Market Value Forecast, by Distribution Channel, 2020-2034
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Drug Class
11.7.2. By Disorder Type
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Asia Pacific Gastric Motility Disorder Drugs Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Class, 2020-2034
12.3.1. Antacids
12.3.2. Antidiarrheals
12.3.3. Calcium-channel Blockers
12.3.4. H2 Blockers
12.3.5. Others (Proton Pump Inhibitors, etc.)
12.4. Market Value Forecast, by Disorder Type, 2020-2034
12.4.1. Upper Digestive Tract
12.4.1.1. Achalasia
12.4.1.2. Gastroesophageal Reflux Disease (GERD)
12.4.1.3. Gastroparesis
12.4.1.4. Dumping Syndrome
12.4.2. Lower Digestive Tract
12.4.2.1. Intestinal Pseudo-obstruction
12.4.2.2. Small Intestinal bacterial Overgrowth (SIBO)
12.4.2.3. Pelvic Dyssynergia
12.4.2.4. Hirschsprung’s Disease
12.5. Market Value Forecast, by Distribution Channel, 2020-2034
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Drug Class
12.7.2. By Disorder Type
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. Latin America Gastric Motility Disorder Drugs Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Class, 2020-2034
13.3.1. Antacids
13.3.2. Antidiarrheals
13.3.3. Calcium-channel Blockers
13.3.4. H2 Blockers
13.3.5. Others (Proton Pump Inhibitors, etc.)
13.4. Market Value Forecast, by Disorder Type, 2020-2034
13.4.1. Upper Digestive Tract
13.4.1.1. Achalasia
13.4.1.2. Gastroesophageal Reflux Disease (GERD)
13.4.1.3. Gastroparesis
13.4.1.4. Dumping Syndrome
13.4.2. Lower Digestive Tract
13.4.2.1. Intestinal Pseudo-obstruction
13.4.2.2. Small Intestinal bacterial Overgrowth (SIBO)
13.4.2.3. Pelvic Dyssynergia
13.4.2.4. Hirschsprung’s Disease
13.5. Market Value Forecast, by Distribution Channel, 2020-2034
13.5.1. Hospitals
13.5.2. Biopharmaceutical Companies
13.5.3. Research Organizations and Academic Institutes
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Drug Class
13.7.2. By Disorder Type
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Middle East & Africa Gastric Motility Disorder Drugs Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Drug Class, 2020-2034
14.3.1. Antacids
14.3.2. Antidiarrheals
14.3.3. Calcium-channel Blockers
14.3.4. H2 Blockers
14.3.5. Others (Proton Pump Inhibitors, etc.)
14.4. Market Value Forecast, by Disorder Type, 2020-2034
14.4.1. Upper Digestive Tract
14.4.1.1. Achalasia
14.4.1.2. Gastroesophageal Reflux Disease (GERD)
14.4.1.3. Gastroparesis
14.4.1.4. Dumping Syndrome
14.4.2. Lower Digestive Tract
14.4.2.1. Intestinal Pseudo-obstruction
14.4.2.2. Small Intestinal bacterial Overgrowth (SIBO)
14.4.2.3. Pelvic Dyssynergia
14.4.2.4. Hirschsprung’s Disease
14.5. Market Value Forecast, by Distribution Channel, 2020-2034
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Drug Class
14.7.2. By Disorder Type
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
15.3.1. Pfizer Inc.
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. The Takeda Pharmaceutical Company Limited
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Janssen Pharmaceuticals
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Sun Pharmaceutical Industries Ltd.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. AbbVie Inc.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Boehringer Ingelheim
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Eli Lilly and Company
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. The Bristol-Myers Squibb Company
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Daiichi Sankyo Company, Limited
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Bausch Health Companies Inc.
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
15.3.11. Mallinckrodt Pharmaceuticals
15.3.11.1. Company Overview
15.3.11.2. Product Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Financial Overview
15.3.11.5. Strategic Overview
15.3.12. Endo International plc
15.3.12.1. Company Overview
15.3.12.2. Product Portfolio
15.3.12.3. SWOT Analysis
15.3.12.4. Financial Overview
15.3.12.5. Strategic Overview
15.3.13. Eisai Co. Ltd.
15.3.13.1. Company Overview
15.3.13.2. Product Portfolio
15.3.13.3. SWOT Analysis
15.3.13.4. Financial Overview
15.3.13.5. Strategic Overview
15.3.14. Ferring Pharmaceuticals
15.3.14.1. Company Overview
15.3.14.2. Product Portfolio
15.3.14.3. SWOT Analysis
15.3.14.4. Financial Overview
15.3.14.5. Strategic Overview
15.3.15. UCB
15.3.15.1. Company Overview
15.3.15.2. Product Portfolio
15.3.15.3. SWOT Analysis
15.3.15.4. Financial Overview
15.3.15.5. Strategic Overview